Möchten Sie immer auf dem neuesten Stand bleiben?

mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari...

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

Stellantis to Present Strategic Plan at May 21 Investor Day  AMSTERDAM, January 29, 2026 – Stellantis N.V. announced today that the Company will present its strategic plan at its Investor Day 2026,...

Maranello (Italy), January 26 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on...

Iveco Group to present 2025 Fourth Quarter and Full Year Results on 12th February 2026 Transactions progressing as planned with the expected dividend for the Defence separation remaining at €5.5-6.0...

CNH to announce 2025 Q4 & Full Year results on February 17 Basildon, January 20, 2026 CNH (NYSE: CNH) will release its financial results for the Fourth Quarter & Full Year of 2025 on...

Maranello (Italy), January 19 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on...

Maranello (Italy), 15 January 2026 - Ferrari N.V. (the “Company”) (NYSE/EXM: RACE) announced today the following corporate calendar for year 20261: Earnings Releases 10 February 2026 - Group results...

Stellantis Announces 2026 Corporate Calendar  AMSTERDAM, January 13, 2026 – Stellantis N.V. announced today the following corporate calendar for 20261: February 26, 2026        Full Year 2025...

Maranello (Italy), January 12 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on...